NO20053860L - COP 1 for behandling av inflammatorisk tarmsykdom. - Google Patents

COP 1 for behandling av inflammatorisk tarmsykdom.

Info

Publication number
NO20053860L
NO20053860L NO20053860A NO20053860A NO20053860L NO 20053860 L NO20053860 L NO 20053860L NO 20053860 A NO20053860 A NO 20053860A NO 20053860 A NO20053860 A NO 20053860A NO 20053860 L NO20053860 L NO 20053860L
Authority
NO
Norway
Prior art keywords
treatment
cop
inflammatory bowel
bowel disease
copolymer
Prior art date
Application number
NO20053860A
Other languages
English (en)
Other versions
NO333579B1 (no
NO20053860D0 (no
Inventor
Rina Ahoroni
Ruth Amon
Basak Kayhan
Ruth Arnon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20053860D0 publication Critical patent/NO20053860D0/no
Publication of NO20053860L publication Critical patent/NO20053860L/no
Publication of NO333579B1 publication Critical patent/NO333579B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører anvendelsen av Kopolymer I (glatiramer acetat), et Kopolymer I -relatert polypeptid, eller et Kopolymer I -relatert peptid, for behandling av inflammatoriske tannsykdommer, slik som Crohns sykdom og ulcerativ kolitt.
NO20053860A 2003-01-21 2005-08-18 Anvendelse av kopolymer 1 for fremstilling av en farmasoytisk sammensetning for behandling av inflammatoriske tarmsykdommer. NO333579B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44113603P 2003-01-21 2003-01-21
PCT/IL2004/000054 WO2004064717A2 (en) 2003-01-21 2004-01-20 Cop 1 for treatment of inflammatory bowel diseases

Publications (3)

Publication Number Publication Date
NO20053860D0 NO20053860D0 (no) 2005-08-18
NO20053860L true NO20053860L (no) 2005-10-20
NO333579B1 NO333579B1 (no) 2013-07-15

Family

ID=32771907

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053860A NO333579B1 (no) 2003-01-21 2005-08-18 Anvendelse av kopolymer 1 for fremstilling av en farmasoytisk sammensetning for behandling av inflammatoriske tarmsykdommer.

Country Status (14)

Country Link
US (1) US8008258B2 (no)
EP (1) EP1592384B1 (no)
AU (1) AU2004206120B2 (no)
CA (1) CA2513567C (no)
DK (1) DK1592384T3 (no)
ES (1) ES2397836T3 (no)
MX (1) MXPA05007711A (no)
NO (1) NO333579B1 (no)
NZ (1) NZ569331A (no)
PT (1) PT1592384E (no)
RU (1) RU2339397C2 (no)
SI (1) SI1592384T1 (no)
WO (1) WO2004064717A2 (no)
ZA (1) ZA200505733B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1459065B1 (en) * 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2565819A1 (en) * 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2732228A1 (en) * 2008-07-25 2010-01-28 The Johns Hopkins University Methods and compositions for treating and preventing autoimmune diseases
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
PL2598165T3 (pl) * 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN106456740B (zh) 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3478300B1 (en) 2016-06-30 2022-08-24 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
IL269893B2 (en) 2017-05-15 2023-10-01 Stem Cell Medicine Ltd Treatment of multiple sclerosis with adipose-derived stem cells
EP3624815A4 (en) 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
ES2408706T3 (es) 1998-09-25 2013-06-21 Yeda Research And Development Co., Ltd. Polipéptidos relacionados con el copolímero 1 para su uso como marcadores de pesos moleculares y para uso terapéutico
WO2000020010A1 (en) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
AU775073C (en) * 1998-11-12 2007-05-03 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
AU2003204344A1 (en) * 2002-05-23 2003-12-11 Milder, Dan George Compositions and methods for the treatment of autoimmune diseases and neurological disorders
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene

Also Published As

Publication number Publication date
US8008258B2 (en) 2011-08-30
AU2004206120A1 (en) 2004-08-05
CA2513567A1 (en) 2004-08-05
SI1592384T1 (sl) 2013-03-29
NO333579B1 (no) 2013-07-15
DK1592384T3 (da) 2012-12-17
WO2004064717A3 (en) 2005-10-13
RU2005126412A (ru) 2006-01-27
ZA200505733B (en) 2006-10-25
CA2513567C (en) 2012-10-23
NZ569331A (en) 2010-08-27
NO20053860D0 (no) 2005-08-18
RU2339397C2 (ru) 2008-11-27
MXPA05007711A (es) 2005-09-30
US20060264354A1 (en) 2006-11-23
EP1592384A4 (en) 2008-12-31
AU2004206120B2 (en) 2009-09-24
EP1592384B1 (en) 2012-10-31
ES2397836T3 (es) 2013-03-11
PT1592384E (pt) 2013-01-28
WO2004064717A2 (en) 2004-08-05
EP1592384A2 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
MXPA05007711A (es) Copolimero 1 para el tratamiento de enfermedades inflamatorias del intestino.
CA2478621A1 (en) Botulinum toxin pharmaceutical compositions
TWI455721B (zh) 癌疫苗組合物
PE20130615A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
PT2298278E (pt) Prevenção e redução da perda de sangue e resposta inflamatória
DK1210430T3 (da) MUC-1-afledte peptider
HRP20041152B1 (hr) Farmaceutske formulacije
MX9402339A (es) Formulacion de proteina.
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
GB9806632D0 (en) Peptide factor
MY199821A (en) Modified lipidated relaxin b chain peptides and their therapeutic use
ES2180629T3 (es) Usos terapeuticos de productos dimeros de proteina bactericida/aumentadora de la permeabilidad.
NO972849L (no) Peptid p277 analoger og farmasöytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes
DK1429800T3 (da) Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose
MXPA02000465A (es) Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6.
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
NO20055692L (no) Intravenos injeksjon av ikkeneurotoksiske plasminogenaktivatorer til behandling av cerebralt slag
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
AU682638B2 (en) Peptide, bronchodilator and blood flow ameliorant
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
HUP0102853A1 (hu) Moraxella catarrhalis-ból származó vegyületek
CY1113827T1 (el) Cop 1 για την αγωγη των φλεγμονωδων παθησεων του εντερου
PT789761E (pt) Scf humano, uma respectiva variante de processamento, sua utilizacao farmaceutica
Critical Care Society of South Africa Working Group Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees